{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:04:25Z","timestamp":1789016665182,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with relapsed\/refractory (r\/r) acute T-lymphoblastic leukemia (T-ALL) have a poor prognosis. We developed donor CD7 chimeric antigen receptor T (CAR-T) cells to salvage r\/r T-ALL patients and obtained encouraging results. Patients who had not received allogeneic (allo-) hematopoietic stem cell transplantation (HSCT) before CAR-T therapy would develop pancytopenia and immunodeficiency for a long period after CD7 CAR-T therapy; therefore, allo-HSCT is needed in these patients. Here, we report two pediatric r\/r T-ALL patients who received donor CD7 CAR-T bridging to allo-HSCT with leukemia-free survival (LFS) and sustained negative minimal residual disease for &amp;gt;2 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Patient 1 was a 10-year-old boy who visited our hospital because of a T-ALL relapse with multiple lymphadenopathies without discomfort. The patient did not achieve remission after one course of induction chemotherapy. The patient then received donor (his father) CD7 CAR-T cells and achieved complete remission (CR). Thirty days after the first CAR-T cell infusion, he received allo-HSCT, and his father was also the donor. His LFS was &amp;gt;3 years. Patient 2 was an 8-year-old boy who was admitted to our hospital with relapsed T-ALL with fever, cough, and mild dyspnea. He did not achieve remission after one course of induction chemotherapy; therefore, he received donor (his father) CD7 CAR-T cells and achieved CR. Twenty-six days after CAR-T cell infusion, the patient received allo-HSCT, with his father as the donor. He has survived for &amp;gt;2 years free of leukemia. At the last follow up, both patients were alive and presented a good quality of life<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The long-term survival of these two patients supports the use of CD7 CAR-T therapy bridging to allo\u2013HSCT as an effective and safe treatment with the capacity to make r\/r T-ALL a curable disease, similar to r\/r acute B-lymphoblastic leukemia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1333037","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T10:05:02Z","timestamp":1709114702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation"],"prefix":"10.3389","volume":"15","author":[{"given":"Yanzhi","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: A randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1048296","article-title":"CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: Long-term follow-up results","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/ relapsed B-cell acute lymphomalastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B8","article-title":"[Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study]","volume":"60","year":"2022","journal-title":"Zhonghua er ke za zhi = Chin J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1103","article-title":"Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation","volume":"13","author":"Bedi","year":"1995","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkx324","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"95","author":"Candoni","year":"2020","journal-title":"A CAMPUS ALL Study Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2309","article-title":"High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"31","author":"O'Brien","year":"2013","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B20","article-title":"Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab","volume":"11","author":"Punatar","year":"2021","journal-title":"Am J Blood Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell Malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell Malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic Malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.013","article-title":"Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic Malignancy","volume":"29","author":"Li","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03450.x","article-title":"Transfusion-associated graft-versus-host disease","volume":"117","author":"Schroeder","year":"2002","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.5.2081","article-title":"CD7- T cells represent a subset of normal human blood lymphocytes","volume":"150","author":"Reinhold","year":"1993","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological Malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1333037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T10:05:06Z","timestamp":1709114706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1333037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2024.1333037"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1333037","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"article-number":"1333037"}}